GAAP revenue of $14.2 million for Q2 2025 beat analyst estimates and Revenue more than doubled year over year in the second quarter, beating analyst estimates. Net loss per share (GAAP) narrowed to ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Regeneron Pharmaceuticals, Inc. saw a significant boost in ownership by Raiffeisen Bank International AG. The bank now ...

RBC Capital analyst Brian Abrahams maintained the stock with a Sector Perform and raised the price target from $688 to $695.

Regeneron Pharmaceuticals, Inc. just announced a quarterly dividend of $0.88 per share, set to delight shareholders with an ...

Second Quarter 2025 Results Key Financial Results Revenue: US$3.68b (up ...

Viking Therapeutics ' ( VKTX 0.28%) shares could rise over the next year by as much as 165% at the midpoint according to some ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Q2 2025 Management View CEO Leonard S. Schleifer reported "Regeneron delivered a strong second quarter, driven by durable ...